Embryonic stem cells: A new avenue to evaluate the effects of chemicals in humans

International Journal of Pharmaceutical Medicine

Volumn 20, Issue 2, 2006, Pages 107-114

  Cezar, Gabriela Gebrin ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL COMPOUND; OXIDOPAMINE; PARAQUAT; TYROSINE 3 MONOOXYGENASE; XENOBIOTIC AGENT;

AUTISM; CARDIOTOXICITY; CELL ISOLATION; CELL TYPE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; EMBRYONIC STEM CELL; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; TORSADE DES POINTES;

EID: 33745712596     PISSN: 13649027     EISSN: 13649027     Source Type: Journal    
DOI: 10.2165/00124363-200620020-00004     Document Type: Review

References (78)

1. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 322: 154-6
2. Capecchi M. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet 2005; 6: 507-12
3. Smithies O. Many little things: one geneticist's view of complex diseases. Nat Rev Genet 2005; 6: 419-25
4. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-7
5. Reubinoff BE, Pera MF, Fong CY, et al. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nature Biotechnol 2000; 18: 399-404
6. Rambhatla L, Chiu CP, Kundu P, et al. Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant 2003; 12: 1-11
7. Kehat I, Gepstein A, Spira A, et al. High-resolution electrophysiological assessment of human embryonic stem cell-derived cardiomyocytes: a novel in vitro model for the study of conduction. Circ Res 2002; 91: 659-61
8. Ben-Hur T, Idelson M, Khaner H, et al. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 2004; 22: 1246-55
9. Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005; 25: 4694-705
10. Thomas J. Cell sources and support programs for stem cell research and cell-based therapy in the USA. Fetal Diagn Ther 2004; 19: 12-7
11. Healy L, Hunt C, Young L, et al. The UK Stem Cell Bank: its role as a public research resource centre providing access to well-characterized seed stocks of human stem cell lines. Adv Drug Deliv Rev 2005; 57: 1981-8
12. Levenstein M, Ludwig TE, Xu RH, et al. Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells 2006 Mar; 24 (3): 568-74
13. Li Y, Powel S, Brunette E, et al. Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. Biotechnol Bioeng 2005; 91: 688-98
14. Menendez P, Wang L, Bhatia M. Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. Curr Gene Ther 2005; 5: 375-85
15. Zwaka TP, Thomson JA. Homologous recombination in human embryonic stem cells. Nat Biotechnol 2003; 21: 359-21
16. Zeng X, Cai J, Chen J, et al. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 2004; 22: 925-40
17. Heijne WH, Kienhuis AS, van Ommen B, et al. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev Proteomics 2005; 2: 767-80
18. Portier CJ, Schwartz DA. The NIEHS and the National Toxicology Program: an integrated scientific vision. Environ Health Perspect 2005; 113: A440
19. Oser BL. Toxicology then and now. Regul Toxicol Pharmacol. 1987; 7: 435-43
20. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004; 3: 234-3
21. Larry D, Pageaux JP. Drug-induced acute liver failure. Eur J Gastroenterol Hepatol 2005; 17: 141-3
22. Zhu W, Song L, Zhang H, et al. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos 2000; 28: 186-91
23. McCormack AL, Thiruchelvam M, Manning-Bog AB, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002; 10: 119-35
24. Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. Int J Devl Neurosci 2005; 23: 189-99
25. Gasset T. Genetics of Parkinson's disease. Curr Opin Neurol 2005; 18: 333-9
26. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-2
27. Cory-Slechta DA, Thiruchelvam M, Barlow BK, et al. Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 2005; 113: 1343-70
28. Thiruchelvam M, McCormack A, Richfield EK. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 2003; 18: 589-600
29. Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson's disease. Neurotoxicology 2002; 23: 487-502
30. Manning-Bog AB, McCormack AL, Purisai MG, et al. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003; 23: 3095-9
31. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40
32. Peng J, Stevenson FF, Doctrow SR. Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease. J Biol Chem 2005; 280: 32194-8
33. Tuchsen F, Jensen AA. Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993. Scand J Work Environ Health 2000; 34: 359-62
34. Kobori N, Waymire JC, Haycock JW, et al. Enhancement of tyrosine hydroxylase phosphorylation and activity by glial cell line-derived neurotrophic factor. J Biol Chem 2004; 359: 2182-91
35. Lee SH, Lumelsky N, Studer L, et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nature Biotechnol 2000; 18: 675-9
36. Yan Y, Yang D, Zarnowska ED. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 2005; 23: 781-90
37. Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nature Rev Genet 2001; 2: 943-55
38. Santangelo SL, Tsatsanis K. What is known about autism: genes, brain, and behavior. Am J Pharmacogenomics 2005; 5: 71-92
39. Mulder EJ, Anderson GM, Kema IP, et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry 2004; 43: 491-9
40. Devlin B, Cook EH, Coon H, et al. Autism and the serotonin transporter: the long and short of it. Mol Psychiatry 2005; 10: 1110-6
41. Moore ML, Eichner SF, Jones JR. Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Ann Pharmacother 2004; 38: 1515-9
42. Buxbaum JD, Silverman J, Keddache M, et al. Linkage analysis for autism in a subset of families with obsessive-compulsive behaviors: evidence for an autism susceptibility gene on chromosome 1 and further support from susceptibly genes on chromosome 6 and 19. Mol Psychiatry 2004; 9: 144-50
43. D'Amelio M, Ricci I, Sacco R, et al. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environmental interactions. Mol Psychiatry 2005; 10: 1006-16
44. Geier DA, Geier MR. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit 2005; 11: 167-70
45. Miyazaki K, Narita N, Narita M, et al. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int J Devl Neurosci 2005; 23: 287-97
46. Mutter J, Naumann J, Schneider R, et al. Mercury and autism: accelerating evidence? Neuro Endocrinol Lett 2005 Oct; 26 (5): 439-46
47. Meadows M. IOM report: no link between vaccines and autism. FDA Consumer 2004; 38: 18-9
48. Ip P, Wong V, Ho M, et al. Mercury exposure in children with autistic spectrum disorder: case-control study. J Child Neurol 2004; 19: 431-4
49. Salli U, Reddy AP, Salli N, et al. Serotonin neurons derived from rhesus monkey embryonic stem cells: similarities to CNS serotonin neurons. Exp Neurol 2004; 188: 351-64
50. Ye W, Shimamura K, Rubenstein JL, et al. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 1998; 93: 755-66
51. Barton HA, Cogliano VJ, Flowers L, et al. Assessing susceptibility from early-life exposure to carcinogens. Environ Health Perspect 2005; 113: 1125-33
52. Cavero I, Mestre M, Guillon JM, et al. Drugs that prolong QT as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp Opin Pharmacother 2000; 2: 947-73
53. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug target, and side effects. N Engl J Med 2003; 348: 538-49
54. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 344: 3588-90
55. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-434
56. Lavon N, Yanuka O, Benvenisty N. Differentiation and isolation of hepatic-like cells from human embryonic stem cells. Differentiation 2004; 72: 234-8
57. Schultz L. Discovery toxicology finds out why good drugs go bad. Drug Discov Dev. Epub 2004 Nov
58. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003; 2: 439-47
59. Kola I, Landis L. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-5
60. Leishman DJ, Helliwell R, Wakerall J, et al. Effects of E-4031, cisapride, terfenadine and terodiline on cardiac repolarisation in canine Purkinje fibre and HERG channels expressed in HEK323 cells. Br J Pharmacol 2000; 132: 134-8
61. Noda T, Takaki H, Kurita T. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J. 2002; 23: 975-83
62. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 2006 Mar-Apr; 53 (2): 87-105
63. Splawski I, Timothy KW, Decher N. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A 2005; 102: 8089-96
64. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J Electrocardiol 2004; 37 Suppl.: 15-24
65. Chaudhary KM, Barrezueta NX, Bauchmann MB, et al. Embryonic stem cells in predictive cardiotoxicity: laser capture microscopy enables assay development. Toxicol Sci 2006; 90: 149-58
66. He J, Ma Y, Lee Y, et al. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 2003; 93: 28-9
67. Maltsev VA, Wobus AM, Rohwedel J, et al. Cardiomyocytes differentiated in vitro from embryonic stem cells developmentally express cardiac-specific genes and ionic currents. Circ Res 1994; 75: 232-44
68. Dolnikov K, Shilkrut M, Zeevi-Levin N, et al. Functional properties of human embryonic stem cell-derived cardiomyoctes. Ann N Y Acad Sci 2005; 1047: 66-75
69. Snyder EY, Hinman LM, Kalichman MW. Can science resolve the ethical impasse in stem cell research? Nature Biotechnol 2006; 24: 397-400
70. Steinbrook R. Egg donation and human embryonic stem-cell research. N Engl J Med 2006; 314: 284-6
71. Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24: 185-7
72. Meissner A, Jaenisch R. Generation of nuclear transfer-derived pluripotent ES cells from cloned Cdx2-deficient blastocysts. Nature 2006; 439: 212-5
73. Chung Y, Klimanskaya I, Becker S, et al. Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres. Nature 2006; 439: 216-9
74. Cowan CA, Atienza J, Melton DA, et al. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005; 349: 1339-73
75. Ding S, Schultz PG. A role for chemistry in stem cell biology. Nat Biotechnol 2004; 22: 832-40
76. Greaves P, Goonetilleke R, Nunn G, et al. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53: 3919-24
77. Spielman H, Poh I, Doering B, et al. The embryonic stem cells test, an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. In Vitro Toxicol 1997; 10: 119-35
78. Pellizzer C, Bello E, Adler S, et al. Detection of tissue specific effects by methotrexate on differentiating mouse embryonic stem cells. Birth Defects Res B Dev Reprod Toxicol 2004; 71: 335-41